Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06836063 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
A Phase 2 study of Major Depressive Disorder (MDD), sponsored by Suven Life Sciences Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT06836063 is a Phase 2 study of Major Depressive Disorder (MDD) that is active but no longer recruiting, run by Suven Life Sciences Limited. The registered enrollment target is 195 participants, above the 150-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06836063, a Phase 2 study of Major Depressive Disorder (MDD), is active but no longer recruiting, sponsored by Suven Life Sciences Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ropanicant
Study Locations (20)
California
- Advanced Research Center, Inc. - Anaheim
- ProScience Research Group - Culver City
- Behavioral Research Specialists, LLC - Glendale
- Synergy San Diego - Lemon Grove
- Excell Research, Inc. - Oceanside
- ATP Clinical Research - Orange
- Collaborative Neuroscience Research - Torrance
Florida
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Premier Clinical Research Institute, Inc - Miami
- Clinical Neuroscience Solutions, Inc. - Orlando
- Panhandle Research and Medical Clinic LLC - Pensacola
- ForCare Clinical Research - Tampa
Georgia
- Atlanta Center for Medical Research - Atlanta
- CenExcel iResearch LLC - Decatur
- CenExcel iResearch LLC - Savannah
Arkansas
- Woodland International Research Group LLC - Little Rock
- Woodland Research Northwest - Rogers
Illinois
- Chicago Research Center Inc. - Chicago
Michigan
- Neurobehavioral Medicine Group - Bloomfield Hills
Mississippi
- Precise Research Centers - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06836063
The ClinicalTrials.gov registry entry for NCT06836063 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 150-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (30% higher). The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06836063 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06836063 about?
NCT06836063 is a clinical study titled "Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients". The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
What is the current status of trial NCT06836063?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2025-07-15. Estimated completion is 2026-02-28.
What conditions does trial NCT06836063 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT06836063?
The interventions under investigation include: Placebo (DRUG), Ropanicant (DRUG).
Who is sponsoring clinical trial NCT06836063?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06836063 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
A Study in Patients With Major Depressive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.